Valor Saxenda

Novo Nordisk Announces Expanded Access and Value Proposition for Saxenda® in Weight Management Therapy

Plainsboro, New Jersey – February 5, 2026 – Novo Nordisk, a global leader in diabetes and obesity care, today reaffirms the strong value of Saxenda® (liraglutide) injection 3 mg as a proven, once-daily treatment option for chronic weight management in adults and adolescents with obesity or overweight with weight-related medical problems.

Saxenda®, the first GLP-1 receptor agonist approved specifically for weight management, continues to deliver meaningful and sustained results when used as an adjunct to a reduced-calorie diet and increased physical activity. Clinical evidence demonstrates average weight loss of 5–10% of baseline body weight over 12 months in many patients, with a significant proportion achieving ≥10% reduction – outcomes that translate into improved cardiometabolic health, quality of life, and reduced risk of obesity-related complications.

“As the demand for effective obesity treatments remains high in 2026, we are committed to highlighting the established value of Saxenda®,” said Dave Moore, Executive Vice President, Corporate Development at Novo Nordisk. “Saxenda® has helped hundreds of thousands of people achieve clinically meaningful weight loss since its launch, offering a reliable, well-tolerated option backed by extensive real-world and clinical data. Our focus remains on ensuring broad awareness of its benefits while supporting affordability programs and insurance navigation.”

Key highlights of Saxenda®’s value include:

• Proven Efficacy: In pivotal trials and long-term extensions, patients on Saxenda® experienced superior weight loss compared to placebo, with many maintaining results beyond the initial treatment period.
• Broad Indication: Approved for adults with BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity) and adolescents aged 12–17 years with obesity (body weight ≥60 kg).
• Convenient Dosing: Once-daily subcutaneous injection with a prefilled pen, titrated gradually from 0.6 mg to the maintenance dose of 3.0 mg.
• Safety Profile: Well-characterized over more than a decade of use, with gastrointestinal side effects being the most common (typically transient) and a favorable benefit-risk profile when prescribed appropriately.

Novo Nordisk continues to invest in patient support through the NovoCare® platform, which provides tools to check insurance coverage, explore savings offers (including potential co-pay as low as $25 for eligible patients in select programs), and access educational resources. The list price (Wholesale Acquisition Cost) for a 5-pen package remains $1,349.02, though actual out-of-pocket costs vary significantly based on insurance, coupons, and pharmacy discounts – often substantially lower through assistance programs.

Despite ongoing supply dynamics in the GLP-1 class, Novo Nordisk confirms continued production and distribution of Saxenda® to meet patient needs, with efforts to minimize disruptions.

Healthcare providers and patients are encouraged to visit www.saxenda.com for the latest information on Saxenda®, including full prescribing information, safety considerations, and affordability options.

About Novo Nordisk Novo Nordisk is a leading global healthcare company with more than 100 years of innovation in diabetes and obesity care. The company is also advancing treatments in rare diseases, hemophilia, growth disorders, and other serious chronic conditions. Novo Nordisk employs approximately 65,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com.

Media Contact: Novo Nordisk Media Relations media@novonordisk.com +1 (609) 786-XXXX (office hours)

Important Safety Information Saxenda® is a prescription medication. It is not for use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or in those with a history of serious hypersensitivity to liraglutide or any components of Saxenda®. Serious side effects may include pancreatitis, gallbladder problems, low blood sugar, increased heart rate, kidney problems, suicidal thoughts or actions, and allergic reactions. Common side effects include nausea, diarrhea, constipation, vomiting, and injection site reactions. Please see full Prescribing Information, including Boxed Warning, at www.saxenda.com.

This press release contains forward-looking statements. Actual results may differ materially due to various risks and uncertainties.